Zusammenfassung
Persönlichkeitsstörungen sind durch eine ausgeprägte Störung der charakterlichen Konstitution und des Verhaltens gekennzeichnet. Diese Störung äußert sich in der Beeinträchtigung mehrerer Bereiche der Persönlichkeit wie der Affektivität, des Denkens und der sozialen und zwischenmenschlichen Beziehungen. Persönlichkeitsstörungen beginnen in der Jugend und können eine lebenslange Entwicklung nehmen. Sie manifestieren sich in typischer Form im frühen Erwachsenenalter.
This is a preview of subscription content, log in via an institution.
Preview
Unable to display preview. Download preview PDF.
Literaturverzeichnis
Bateman AW, Fonagy P (2000) Effectiveness of psychotherapeutic treatment of personality disorder. Br J Psychiatry 177: 138–143
Becker DF, Grilo CM, Morey LC, Walker ML, Edell WS, McGlashan TH (1999) Applicability of personality disorder criteria to hospitalized adolescents: evaluation of internal consistency and criterion overlap. J Am Acad Child and Adolesc Psychiatry 38: 200–205
Bellino S, Paradiso E, Bogetto F (2005) Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 66: 1111–1115
Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E (1998) Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 59: 103–107
Bogenschutz MP, Nurnberg GH (2004) Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 65: 104–109
Cardish RJ (2007) Psychopharmacologic management of suicidality in personality Disorders. Can J Psychiatry [Suppl 1] 52: 115S–127S
Coccaro EF (1993) Psychopharmacologic studies in patient with personality disorders: review and perspective. J Personal Disord 154[Suppl 2]: 181–192
Coccaro EF, Kavoussi RJ (1997) Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psychiatry 54: 1081–1088
Cowdry R, Gardner DL (1988) Pharmacotherapy in borderline personality disorder. Arch Gen Psychiatry 45: 111–119
De la Fuente und Lotstra (1994) A trial of carbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 4: 479–486
Fahlen T, Nilsson HL, Borg K, Humble M, Pauli U (1995) Social phobia: the clinical efficacy and tolerability of the monoamine oxidase — A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 92: 351–358
Gerlach M, Baving L, Fegert J (2006) Therapie mit Lithiumsalzen in der Kinder-und Jugendpsychiatrie — Klinische Wirksamkeit und praktische Empfehlungen. Z Kinder-Jugendpsychiatr 34: 181–189
Goldberg SC, Schulz SC, Schulz PM, Resnick RJ, Hamer RM, Friedel RO (1986) Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo. Arch Gen Psychiatry 43: 680–686
Herpertz S, Wenning B (2003) Spezifische Persönlichkeitsstörungen: Diagnose, Ätiologie und Psychotherapie. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme, Stuttgart New York, 61–147
Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ & WFSBP Task Force on Personality Disorders (2007) World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Personality Disorders. World J Biol Psychiatry 8: 212–244
Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB (2003) Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 28: 1186–1197
Kapfhammer HP (2003) Pharmakotherapie bei Persönlichkeitsstörungen. In: Herpertz S, Saß H (Hrsg) Persönlichkeitsstörungen. Thieme, Stuttgart New York, 152–164
Keshavan M, Shad M, Soloff P, Schooler N (2004) Efficacy and tolerability of olanzapine in the treatment of schizotypal personality disorder. Schizophr Res 71: 97–101
Kirrane RM, Siever LJ (2000) New perspectives on schizotypical personality disorder. Curr Psychiatry Rep 48: 1–5
Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ (2003) Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 64: 628–634
Links PS, Steiner M, Boiago I (1990) Lithium therapy for borderline patients: preliminary findings. J Pers Dis 4: 173–181
Malone RP, Delaney MA, Luebbert JF, Cater J, Campbell M (2000) A double-blind placebo-controlled study of lithium in hospitalized aggressive children and adolescents with conduct disorders. Arch Gen Psychiatry 57: 649–654
Markovitz PJ, Wagner SC (1995) Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 31: 773–777
Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P (2006) Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind placebo-controlled study. Am J Psychiatry 163: 833–838
Nosé M, Cpriani A, Biancosino B, Grassi L, Barbui C (2006) Efficacy of pharamcotherapy against core traits of borderline personality disorder: meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 21: 345–353
Paris J (2002) Chronic suicidality among patients with borderline personality disorder. Psychiatr Serv 53: 738–742
Pascual JC, Soler J, Puigdemont D, Pérez-Egea R, Tiana T, Alvarez E, Pérez V (2008) Ziprasidone in the treatment of borderline personality disorder: a double-blind, placebo-controlled, randomized study. J Clin Psychiatry 69: 603–608
Perry JC, Banon MD, Eanne F (1999) Effectiveness of psychotherapy for personality disorders. Am J Psychiatry 156: 1312–1321
Quante A, Röpke S, Merkl A, Anghelescu I, Lammers CH (2008) Pharmakologische Behandlung von und bei Persönlichkeitsstörungen. Fortschr Neurol Psychiat 76: 139–148
Salbach-Andrae H, Bürger A, Klinkowski N, Lenz K, Pfeiffer E, Fydrich T, Lehmkuhl U (2008) Diagnostik von Persönlichkeitsstörungen im Jugendalter nach SKID-II. Z Kinder-Jugendpsychiatr 36: 117–125
Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki E (1995) Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 15: 23–29
Schultz SC, Camlin KL, Berry SA, Jesberger JA (1999) Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 46: 1429–1435
Simpson EB, Yen S, Costello E, Rosen, K, Begin A, Pistorello J, Pearlstein T (2004) Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 65: 379–385
Soler J, Pascual JC, Campins J, Barrachina J, Puigdemont D, Alvarez E, Pérez V (2005) Doubleblind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 162: 1221–1224
Soloff PH, Nathan RS, GeorgeA, PM, Cornelius JR, Perel JM, Ulrich RF (1986) Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 50: 377–385
Soloff PH, Nathan RS, George A, Schultz PM Cornelius JR, Perel JM, Ulrich RF (1993) Progress in pharmacotherapy of borderline disorders: a double blind study of amitriptyline, haloperidol and placebo. Arch Gen Psychiatry 43: 691–697
Triebwasser J, Siever LJ (2007) Pharmacotherapy of personality disorders. J Ment Health 16: 5–50
Verkes RJ, Van der Mast RC, Hengeveld MW, Tuyl JP, Zwinderman AH, Van Kempen GM (1998) Reduction by paroxetine of suicidal behavior in patients with repeated suicide attempts but not major depression. Am J Psychiatry 155: 543–547
Wewetzer C, Herpertz S, Herpertz-Dahlmann B, Oehler K-U (2007) Persönlichkeitsstörungen (F60, F61). In: In: Deutsche Gesellschaft für Kinder-und Jugendpsychiatrie und Psychotherapie, Bundesarbeitsgemeinschaft Leitender Klinikärzte für Kinder-und Jugendpsychiatrie und Psychotherapie und Bundesverband der Ärzte für Kinder-und Jugendpsychiatrie und Psychotherapie (Hrsg) Leitlinien zu Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes-und Jugendalter, 3. überarb. und erw. Aufl. Deutscher Ärzte-Verlag, Köln, 141–152
Zanarini MC, Frankenburg FR (2001) Olanzapine treatment of female borderline personality disorder patients: a double-blind, placebo-controlled pilot study. J Clin Psychiatry 62: 849–854
Zanarini MC, Frankenburg FR, Parachini EA (2004) A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 7: 903–907
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer-Verlag/Wien
About this chapter
Cite this chapter
Romanos, M., Wewetzer, C. (2009). Persönlichkeitsstörungen (F60, F61). In: Gerlach, M., Warnke, A., Mehler-Wex, C., Walitza, S., Wewetzer, C. (eds) Neuro-Psychopharmaka im Kindes- und Jugendalter. Springer, Vienna. https://doi.org/10.1007/978-3-211-79275-9_25
Download citation
DOI: https://doi.org/10.1007/978-3-211-79275-9_25
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-79274-2
Online ISBN: 978-3-211-79275-9
eBook Packages: Medicine (German Language)